A recent phase III trial showed better survival with additional LAT, indicating that LAT could be considered for the treatment of synchronous oligometastatic disease in patients with EGFR-mutated NSCLC [30,34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.